Clinical trials: Digestive System Cancer
Gastric Cancer
A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer
This study will evaluate the disease free survival rate of a combination of capecitabine [Xeloda] and oxaliplatin (XELOX) with trastuzumab [Herceptin] in patients with resectable gastric cancer.
- Trial name
- NCT01130337
- Testing
- Capecitabine [Xeloda], Oxaliplatin, Trastuzumab [Herceptin]
- Where
- 30 sites in Spain
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Cancer
Minocycline Study in Pancreatic Cancer Patients
The goal of this clinical research study is to learn if minocycline can reduce the side effects of chemotherapy in patients with pancreatic cancer. In this study, minocycline will be compared to a placebo.
- Trial name
- NCT01693523
- Testing
- Minocycline, Questionnaires
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma, Cholangiocellular Carcinoma
Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers
This is a single arm phase II trial of Gemcitabine and Oxaliplatin (Gem-Ox) with Erlotinib (Tarceva) for the treatment of hepatocellular carcinoma (HCC) and biliary tree cancer (BTC) patients with platelet counts 100,000/µL.
- Conditions
- Hepatocellular Carcinoma, Cholangiocellular Carcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct, Bile Duct Cancer
- Trial name
- Gem-ox (NCT00832637)
- Testing
- Cisplatin, Erlotinib, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- New Mexico Cancer Research Alliance
Advanced Solid Tumors, Pancreatic Cancer
Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours
This study is an open label, two-part, First in Human (FIH) Phase 1/2 dose-finding study designed to determine the safety, tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and proof-of-concept (POC) of OMO-103 in…
- Conditions
- Advanced Solid Tumors, Pancreatic Cancer, CRC
- Trial name
- MYCure (NCT04808362)
- Testing
- OMO-103
- Where
- 3 sites in Spain
- Volunteers
- 22 people
- Sponsor
- Peptomyc S.L.
Gastrointestinal Stromal Tumor
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed…
- Trial name
- NCT01068769
- Testing
- regorafenib
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Suzanne George, MD
Cholangiocarcinoma, Liver and Intrahepatic Bile Duct Carcinoma
Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
This phase II trial studies how well ramucirumab works in treating patients with previously treated biliary cancers that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced)…
- Conditions
- Cholangiocarcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Stage III Gallbladder Cancer AJCC v7, Stage III Intrahepatic Cholangiocarcinoma AJCC v7
- Trial name
- NCT02520141
- Testing
- Laboratory Biomarker Analysis, Ramucirumab
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Pancreatic Cancer
First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem
The pancreas cancer is the 4th cause of death. All stage confused, the survival at 5 years is note over 5 %. At metastatic stage, the pancreatic adenocarcinoma is an incurable disease with the survival median of 2-4 months…
- Trial name
- PANOPTIMOX (NCT02352337)
- Testing
- FOLFIRINOX, LV5FU2, FOLFIRI.3
- Where
- 54 sites in France
- Volunteers
- 276 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Liver Cancer, Hepatocellular Carcinoma
A Pilot Study to Assess Theragnostically Planned Liver Radiation to Optimize Radiation Therapy
The purpose of this study is to compare radiation treatment plans that are designed for patients with liver cancer. One treatment plan will be created using routine procedures and scans normally performed for radiation treatment…
- Conditions
- Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma
- Trial name
- NCT03338062
- Testing
- Hepatobiliary Iminodiacetic Acid (HIDA) scan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Indiana University
Rectal Neoplasms
A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)
The purpose of this adaptive trial is to compare the progression-free survival of participants with metastatic rectal carcinoma when treated with intravenous (IV) dalotuzumab (MK-0646) + irinotecan therapy relative to…
- Trial name
- NCT01609231
- Testing
- Dalotuzumab, Irinotecan, Cetuximab
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
Colon Cancer
Efficacy of Morning-only Bowel Preparation for Afternoon Colonoscopy.
The study aims to study the adequacy of bowel preparation (colon cleansing) for afternoon colonoscopies. The conventional regimen of giving bowel prep on the evening prior to the day of the colonoscopy will be compared with that…
- Trial name
- CCF (NCT00687830)
- Testing
- Polyethylene Glycol afternoon, Polyethylene Glycol morning
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Cleveland Clinic Florida
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fluorouracil and leucovorin calcium, work in different ways to stop the growth…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00942266
- Testing
- fluorouracil, leucovorin calcium, vorinostat
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Roswell Park Cancer Institute
Gastric Cancer, Dumping Syndrome
Gastrectomy, Eating Behaviour and GLP-1
Patients who have undergone gastrectomy (removal of the stomach) to treat or prevent cancer are known to have a significantly reduced quality of life. To date, there is very little information on the physiological causes of this.
- Trial name
- NCT02971631
- Testing
- Exendin 9-39
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Aerodigestive Tract Cancer, Lung Cancer
A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer
The primary aim is to study the effects of vorinostat on cyclin E, cyclin D1 and Ki-67 expression in aerodigestive tract tumors (lung, esophagus, and head and neck).
- Conditions
- Aerodigestive Tract Cancer, Lung Cancer, Esophageal Cancer, Head and Neck Cancer
- Trial name
- NCT00735826
- Testing
- Vorinostat
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Colorectal Cancer, Liver Metastases
Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
Background: Many people with colorectal cancer get liver metastases. Standard treatment for this is a combination of chemotherapy drugs. Directing the chemotherapy to the liver may be effective.
- Conditions
- Colorectal Cancer, Liver Metastases, Colorectal Adenocarcinoma, Colorectal Cancer With Hepatic Metastases
- Trial name
- NCT03366155
- Testing
- Codman 3000 constant flow pump catheter, Panitumumab, FUDR-Dex
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Tumor Pathway Activations Inhibited by Dovitinib
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
The purpose of this signal seeking study was to determine whether treatment with dovitinib (TKI258) demonstrated sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further…
- Trial name
- SIGNATURE (NCT01831726)
- Testing
- Dovitinib (TKI258)
- Where
- 49 sites in United States
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Gastrointestinal Cancer, Biliary Tract Cancer
Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase
Part 1: Dose-Escalation Phase (Phase 1b) The primary objective is to assess the safety and tolerability of increasing doses of D07001 softgel in patients with unresectable locally advanced or metastatic gastrointestinal (GI)…
- Trial name
- NCT03531320
- Testing
- D07001-softgel capsules
- Where
- 4 sites in Taiwan
- Volunteers
- 19 people
- Sponsor
- InnoPharmax Inc.
Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
This phase II trial studies the side effects and how well nivolumab with or with ipilimumab works in treating patients with liver cancer that can be removed by surgery.
- Trial name
- NCT03222076
- Testing
- Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer
This is a randomized pilot study to evaluate and to compare the completion rates of Total Neoadjuvant chemotherapy with FLOT ( FLOT-TNT) and perioperative chemotherapy with FLOT ( FLOT-POP).
- Trial name
- TOGAR (NCT05567835)
- Testing
- Fluorouracil, Leucovorin, Oxaliplatin
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- Baylor College of Medicine
Metastatic Colorectal Cancer
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
FC-6 is a Phase II, multi-center clinical trial for patients with unresectable, wild-type K-RAS, colorectal cancer with metastases confined to the liver.
- Trial name
- NCT00803647
- Testing
- cetuximab, 5-FU, oxaliplatin
- Where
- 23 sites in United States
- Volunteers
- 20 people
- Sponsor
- NSABP Foundation Inc
Pancreatic Cancer
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer
The purpose of this study is to determine whether patients with locally advanced pancreatic cancer who receive dasatinib added to standard of care (gemcitabine) live longer, compared to patients who receive standard of care…
- Trial name
- LAPC (NCT01395017)
- Testing
- dasatinib
- Where
- 74 sites in United States, Australia and 13 more
- Volunteers
- 202 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.